Aptar Pharma's Obtains Import Licence in China
![](/46/pdcnewsitem/03/43/75/sbzlB9QMCIbjiSR.jpg)
Aptar Pharma has obtained a State Food and Drug Administration (SFDA) import licence approval to deliver its preservative-free multi-dose systems to customers in China.The licence approval represents a further step in Aptar Pharma’s ongoing service development to provide large-scale production services to customers, mainly for its Ophthalmic Squeeze Dispenser (OSD) and its Advanced Preservative Free spray pump (APF).
Aptar Pharma Enlarges its Service Scope in China
In China, the pharmaceutical sector remains dynamic, outpacing growth in developed countries. The import of packaging materials for pharmaceutical products requires an “Examination and approval for packaging materials and containers in direct contact with drugs” from the SFDA before being placed on the market. Now that this import licence approval has been granted for the Ophthalmic Squeeze Dispenser (OSD) and Advanced Preservative-Free Systems (APF), pharmaceutical and biotechnology companies can directly import Aptar Pharma’s preservative-free multi-dose systems into the Chinese market. The OSD is manufactured in a class ISO 7 cleanroom at the Aptar Pharma state-of-the-art production facility in Eingeltingen, Germany.
Preservative-Free Systems are Key to Drug Manufacturers
Preservative-free systems are highly appreciated by patients who experience side effects from preservatives like benzalkonium chloride during chronic use. The APF spray pumps and the OSD systems follow a purely mechanical approach to prevent contamination via the orifice. The applied technology is referred to as “tip seal technology” and well established on other markets.
A key element of Aptar Pharma’s preservative-free technology is a spring-loaded tip seal that keeps the system closed until a defined pressure is reached during actuation and the formulation is dispensed through the orifice. When the pressure drops consequently, the tip seal immediately closes the orifice by an outward movement, which prevents any back-flow of contaminated liquids or particles.
For the venting air, Aptar Pharma uses a sterile filter to stop micro-organisms from entering. The fluid path of these systems is “metal-free”, which means the springs needed for the device operation do not come in contact with the formulation. The technology is widely established and market proven in both nasal and ophthalmic applications.
In addition, the APF spray pumps and the OSD systems are designed to be patient-friendly and easy to use to help improve patient compliance with the medical treatment. The 360° functionality of the APF spray pumps ensures convenient and safe handling; especially for pediatric use. Aptar Pharma’s OSD system is engineered for intuitive handling, smooth actuation and precise and reproducible dosage, all this with pocket sized design.
Aptar Pharma Established in China Since 1996
The import license will help meet market demand in China and further establishes Aptar Pharma’s presence in China, through its production site in Suzhou, near Shanghai. Aptar Pharma Suzhou was established in 1996 and produces pMDI metering valves and spray pumps for the Asian market. The site serves the majority of the local Chinese pharmaceutical companies, whether they are producing drug products for the domestic market or for other Asian regions.
“We are pleased to announce the import licence for the OSD technology and APF pump technology to China. We have had tremendous success marketing these technologies in other regions of the world and we are confident that our customers and consumers in China will value the benefits of our preservative free systems. As with any of our technologies, we continue to invest in ways to even further improve our devices as we adapt to our customers’ future needs and expectations”, said Matthias Birkhoff, Vice President Business Development for Aptar Pharma CHC Division.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance